Claims

Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.

4 results

Cholesteryl ester transfer protein (CETP) inhibitors — torcetrapib, dalcetrapib, evacetrapib, anacetrapib, obicetrapib — and their trials (e.g., ILLUMINATE, dal-OUTCOMES, ACCELERATE, REVEAL), lipid effects (raised HDL, lowered LDL), cardiovascular outcomes, and safety. Not for other lipid-lowering drug classes.

CETP inhibitors substantially lowered LDL cholesterol but failed to reduce cardiovascular events

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular disease LDL cholesterolimportance · minorImportance 0.30, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Anacetrapib significantly reduced major coronary events in the REVEAL trial

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Non-statin lipid-lowering therapyimportance · minorImportance 0.30, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Evacetrapib lowered LDL cholesterol without reducing cardiovascular events

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular disease LDL cholesterolimportance · settledImportance 0.15, from 0 to 1 · settled: uncontested, so low even when much depends on it. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Torcetrapib lowered LDL cholesterol but increased cardiovascular events and mortality

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular diseaseimportance · settledImportance 0.20, from 0 to 1 · settled: uncontested, so low even when much depends on it. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Contribute

If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim or a question entirely, propose it below. A proposal is reviewed on its wording; accepted proposals are matched against the graph before they enter it.